Ningbo Menovo Pharmaceutical (603538.SH) released an announcement that the company's wholly-owned subsidiary Ningbo Menovo Pharmaceutical TianKang Co., Ltd. (abbreviated as...)
According to Zhito Finance APP, Ningbo Menovo Pharmaceutical (603538.SH) announced that its wholly-owned subsidiary Ningbo Menovo Pharmaceutical TianKang has recently received the Drug Registration Certificate for Metformin Vildagliptin Tablets (II) issued by the National Medical Products Administration. The indications for this pharmaceutical are: in conjunction with diet and exercise treatment, for adult patients with type 2 diabetes who have poor blood sugar control at the maximum tolerated dose of monotherapy with Metformin or are currently receiving a combination therapy of Vildagliptin and Metformin.
The acquisition of the Drug Registration Certificate for Metformin Vildagliptin Tablets (II) from the National Medical Products Administration signifies that the company has obtained the qualification to produce and sell this pharmaceutical in the domestic market, enhancing the market competitiveness of the company's products and further enriching the company's diabetes medication pipeline. This has a positive effect on the company's operational development.